Italy’s Chiesi is gearing up to acquire US-listed KalVista Pharmaceuticals for an impressive $1.9 billion, signaling a bold leap to expand its rare disease and drug development portfolio, Reuters reports. This landmark deal highlights the growing surge of cross-border investments transforming the pharmaceutical landscape